Clinical effectiveness of gene therapy on critical limb ischemia: a meta-analysis of 5 randomized controlled clinical...

Area of Science:

• Vascular Medicine
• Regenerative Medicine
• Gene Therapy

Background:

• Critical limb ischemia (CLI) is a severe condition with limited treatment options.
• Therapeutic angiogenesis via gene therapy offers a novel approach for CLI management.
• Revascularization may not be an option for all CLI patients.

Purpose of the Study:

• To evaluate the efficacy and safety of gene therapy for treating CLI in patients ineligible for revascularization.
• To synthesize evidence from randomized controlled trials through a meta-analysis.

Main Methods:

• Systematic literature search of PubMed and EMBASE databases (1990-October 2013).
• Inclusion of five randomized placebo-controlled trials involving gene therapy for CLI.
• Meta-analysis of outcomes including major amputation, death, wound healing, and serious adverse events.

Main Results:

• No statistically significant differences were found in major amputation or death at 1 year (RR, 0.83; 95% CI, 0.51-1.39).
• Wound healing at 6 months also showed no significant difference between gene therapy and placebo (RR, 1.55; 95% CI, 0.73-3.28).
• The occurrence of serious adverse events was similar in both gene therapy and control groups (RR, 1.05; 95% CI, 0.97-1.14).

Conclusions:

• Current gene therapy strategies, including fibroblast growth factor 1 and hepatocyte growth factor, do not demonstrate significant clinical benefits for CLI patients lacking revascularization options.
• Gene therapy for CLI appears to have a comparable safety profile to placebo.
• Further research may be needed to explore alternative gene therapy approaches or patient selection criteria for CLI treatment.